| P50 | author | Ja Min Byun | Q41549147 |
| | Sung-Hoon Jung | Q54483318 |
| P2093 | author name string | Yong Park | |
| | Soo-Mee Bang | |
| | Hyewon Lee | |
| | Sung-Soo Yoon | |
| | Youngil Koh | |
| | Jae Joon Han | |
| | Dae Sik Kim | |
| | Seok Lee | |
| | Ki Hwan Kim | |
| | Jun Ho Jang | |
| | Jeong-Ok Lee | |
| | Dong-Yeop Shin | |
| | Won Sik Lee | |
| | Yoo Jin Lee | |
| | Inho Kim | |
| | Yun-Suk Choi | |
| | Ho-Young Yhim | |
| | Korean Adult ALL Working Party, Korean Society of Hematology | |
| P2860 | cites work | Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial | Q31085634 |
| | Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group | Q33428556 |
| | Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. | Q35178966 |
| | Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia | Q35571035 |
| | Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia | Q35602915 |
| | Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia | Q36338763 |
| | Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study | Q36751420 |
| | Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia | Q38425323 |
| | New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia | Q38428357 |
| | Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia. | Q38814341 |
| | BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. | Q39122060 |
| | Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. | Q54348230 |
| | Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols. | Q54484839 |
| | Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) | Q58414406 |
| | Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche de | Q79527735 |
| P433 | issue | 5 | |
| P921 | main subject | leukemia | Q29496 |
| | lymphoblastic leukemia | Q18553852 |
| P304 | page(s) | e187-e190 | |
| P577 | publication date | 2017-01-12 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors | |
| P478 | volume | 102 | |